Surrozen, Inc./DE Business Combination, Acquisition Related Costs
Surrozen, Inc./DE (SRZN) reported Business Combination, Acquisition Related Costs of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2023-03-31
- Surrozen, Inc./DE business combination, acquisition related costs for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE business combination, acquisition related costs for the quarter ending 2021-12-31 was $17.00K.
- Surrozen, Inc./DE business combination, acquisition related costs for the quarter ending 2020-12-31 was $0.00.
- Surrozen, Inc./DE business combination, acquisition related costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Surrozen, Inc./DE business combination, acquisition related costs for fiscal 2021 was $409.00K.
- Surrozen, Inc./DE business combination, acquisition related costs for fiscal 2020 was $0.00.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $409.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $392.00K 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $0.00 10-K · filed 2022-03-28 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |